Logo

Celera Cuts Third Database Deal With Novartis Pharma

Apr 23, 1999
Premium

ROCKVILLE, Md.--Celera Genomics here said it has entered a five-year deal to provide a subscription to its database products and early access to new genomic information to Novartis Pharma. Through the subscription, which includes access to associated bioinformatics tools for viewing, browsing, and analyzing genomics information, Novartis will gain access to Celera's human gene index, its Drosophila genome database, and its human genome database. Celera has also licensed its database products to Pharmacia and Upjohn and Amgen. Terms of the deals have not been announced.

Filed under

Informatics
Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.